SCHEMBL23212049

SCHEMBL23212049

CC(C)(C)OC(=O)N1CCC(N2CC3(CC3)c3cc(Cl)ccc32)CC1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.47
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
STS P08842 4/20 0.44
TP53 P04637 1/20 0.44
CNR1 P21554 2/20 0.42
CNR2 P34972 1/20 0.42
HRH3 Q9Y5N1 2/20 0.41
OXTR P30559 1/20 0.41
AVPR1A P37288 1/20 0.41
MAPT P10636 1/20 0.41
USP2 O75604 1/20 0.41
HPGD P15428 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HSD17B10 Q99714 1/20 0.41
NR3C1 P04150 1/20 0.41
PAK1 Q13153 1/20 0.41
USP30 Q70CQ3 1/20 0.40
GPR119 Q8TDV5 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23211956 0.83 NOTUM (0.51) NOTUMMAPT
SCHEMBL27219049 0.83 NOTUM (0.44) NOTUMMEN1KMT2ASTSCNR1
SCHEMBL5256365 0.81 STS (0.47) NOTUMMEN1KMT2ASTSTP53
SCHEMBL30568000 0.81 STS (0.47) NOTUMMEN1KMT2ASTSTP53
SCHEMBL4993502 0.81 ESR2 (0.48) NOTUMMEN1KMT2ASTSTP53
SCHEMBL1689637 0.79 NOTUM (0.68) NOTUMMEN1KMT2ASTSOXTR
SCHEMBL26915667 0.77 HTR2C (0.51) MEN1KMT2ASTSTP53CNR1
SCHEMBL24187342 0.76 MEN1 (0.48) MEN1KMT2ASTSTP53CNR1
SCHEMBL26916422 0.75 NOTUM (0.55) NOTUMMEN1KMT2ASTSOXTR
SCHEMBL3126834 0.75 GPR119 (0.49) NOTUMMEN1KMT2ASTSTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230117324-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2023-04-20 US disclosed
EP-3768684-B1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS HOFFMANN LA ROCHE (CH) 2023-02-22 EP disclosed
US-20210107920-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2021-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210107920-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS MGLL, LPL, LIPC NOTUM 70/4885MEN1 1218/4885KMT2A 2681/4885
US-20230117324-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS MGLL, LPL, LIPC NOTUM 70/4885MEN1 1218/4885KMT2A 2681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.